#United States #Denver #kidney disease #Fresenius Medical Care #ASN Kidney Week

Fresenius Medical Care's Innovations at ASN Kidney Week 2026

Fresenius Medical Care (FME), recognized worldwide as a leader in renal healthcare solutions, has made significant strides in kidney care innovations. Presenting their latest research at ASN Kidney Week 2026, which takes place from October 21 to 25 in Denver, Colorado, FME aims to revolutionize patient outcomes based on empirical evidence and cutting-edge technology.

A key focus of FME's ongoing research is high-volume hemodiafiltration (HvHDF). Real-world evidence from diverse clinical settings in the U.S. indicates that this treatment modality can yield comparable results to those observed in Europe. Studies highlight that 74% of treatments achieved the target convective dose of 23 liters or more, showcasing the effective implementation of HvHDF through the state-of-the-art 5008X™ CAREsystem.

Charles Hugh-Jones, MD, FRCP, Global Chief Medical Officer of Fresenius Medical Care, emphasized the use of large-scale evidence to advance kidney care standards. “We are committed to improving patient outcomes and our studies reflect this aim. Our focus on HvHDF and innovative therapies highlights how we can better support individuals undergoing dialysis,” said Hugh-Jones.

Key Presentations and Findings

Among the pivotal studies presented at the conference include:

• - High-Volume Hemodiafiltration Success: Analysis confirms that the 5008X™ CAREsystem can regularly achieve recommended goals in U.S. clinical practice, validating the effectiveness of this treatment option.

• - Link Between Body Size and HDF Efficacy: Research explores the correlation between convective volume and patient body size in relation to survival rates, which could lead to personalized treatment approaches.

• - Near-Real-Time Data Utilization: FME’s innovative platform showcases quality improvement by rapidly analyzing real-world clinical data during the U.S. rollout of HvHDF, aiming to track vital metrics such as mortality and treatment adherence.

• - Impact of GLP-1 Receptor Agonists: Research indicates that the use of GLP-1 receptor agonists is associated with significantly decreased mortality and hospitalization rates in dialysis patients, underscoring the importance of integrating advanced pharmacotherapy in treatment plans.

• - Anticoagulation Strategies in Critical Settings: Insights from a multicenter study reveal successful management of anticoagulation in critically ill patients, maintaining treatment efficacy while minimizing side effects.

• - AI-Enhanced Clinical Insights: A groundbreaking study utilizing AI to analyze over 455,000 dialysis treatment notes demonstrated promising accuracy, illustrating the potential of artificial intelligence to transform clinical documentation into actionable data.

Visit FME at ASN Kidney Week

Attendees of ASN Kidney Week 2026 are encouraged to visit Fresenius Medical Care at Booth #571 and the Renal Research Institute at Booth #255. Here, visitors can learn more about the latest innovations, including the 5008X CAREsystem and multiFiltratePRO™.

Conclusion

Fresenius Medical Care's commitment to advancing kidney care through research and innovation is pivotal in addressing the global challenges associated with renal diseases. By leveraging real-world evidence and cutting-edge technology, FME is not only improving patient care but also setting new standards for the future of dialysis and kidney treatment.

For additional information on Fresenius Medical Care’s presence and contributions at ASN Kidney Week 2026, visit Fresenius Medical Care.

Fresenius Medical Care continues to be at the forefront of renal healthcare solutions, ensuring that patients receive the best possible care through innovative treatments and committed research efforts.